Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.

Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.

BACKGROUND: Preemptive therapy with ganciclovir (GCV) based on the results of a cytomegalovirus (CMV) antigenemia assay is a standard strategy for preventing CMV disease after allogeneic hematopoietic cell transplantation (HCT). However, the appropriate threshold of antigenemia-positive cells for de...

Full description

Bibliographic Details
Main Authors: Kana Sakamoto, Hideki Nakasone, Hidenori Wada, Ryoko Yamasaki, Yuko Ishihara, Koji Kawamura, Masahiro Ashizawa, Miki Sato, Kiriko Terasako-Saito, Tomohito Machishima, Shun-ichi Kimura, Misato Kikuchi, Shinichi Kako, Junya Kanda, Rie Yamazaki, Aki Tanihara, Junji Nishida, Yoshinobu Kanda
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3764037?pdf=render

Internet

http://europepmc.org/articles/PMC3764037?pdf=render

Similar Items